首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

DRUG DISCOVERY TODAY
ISSN：1359-6446

DRUG DISCOVERY TODAY

DRUG DISCOV TODAY
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：约6.0个月
新锐分区：医学2区
年发文量：242
影响因子：7.5
JCR分区：Q1

基本信息

《今日药物发现》为发现社区提供了知情的和高度最新的评论。该杂志不仅讨论药物研发相关技术的快速科学发展，还讨论在研发计划、结构和执行中发挥越来越重要作用的管理、商业和监管问题。特色包括国际专家评论、重要发展的新闻和分析、关键科学和战略问题的评论，综述特定治疗领域的最新进展和会议报告。内容包括：·新的治疗策略·高通量筛选·治疗靶点·组合化学、平行合成和文库设计·药物递送· ADME/Tox·关键化合物类别和治疗领域的进展·基因组学和蛋白质组学·自动化和技术·虚拟化学·信息学·商业战略·临床试验和药物发现的其他方面。
1359-6446SCIE/Scopus收录
7.5
点击查看最新影响趋势>
8.1
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学2区
PHARMACOLOGY & PHARMACY 药学
2区
是
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q1
19/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q1
79/353
157
242
点击查看年发文量趋势图>
8%较难约6.0个月-医学-药学
1.3%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
0.00%26.12%-
CiteScore：16.00
SJR：1.742
SNIP：1.626
学科类别分区排名百分位
大类：Pharmacology, Toxicology and Pharmaceutics
小类：Drug Discovery
Q1
6 / 156
大类：Pharmacology, Toxicology and Pharmaceutics
小类：Pharmacology
Q1
15 / 321

期刊高被引文献

Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.08.005
Luxturna: FDA documents reveal the value of a costly gene therapy.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.019
Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.003
Towards the development of human immune-system-on-a-chip platforms
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.10.003
Drug repurposing: a promising tool to accelerate the drug discovery process.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.014
Therapy for glioblastoma: is it working?
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.008
Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.08.009
The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.022
PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.09.001
TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.12.001
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.023
Recent advances in intraocular sustained-release drug delivery devices.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.031
Hydrogels for sustained delivery of biologics to the back of the eye.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.037
Evolution of commercially available compounds for HTS.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.10.016
Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.12.007
Alternative splicing, RNA-seq and drug discovery.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.030
Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.009
Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.002
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.015
3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.09.003
Efficient drug discovery by rational lead hybridization based on crystallographic overlay.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.021
Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.007
Exploring new technologies in biomedical research.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.001
The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.09.011
Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.001
Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.016
Advances in differentiation therapy for osteosarcoma.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.08.010
Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.11.002
The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.018
Unbiased data analytic strategies to improve biomarker discovery in precision medicine.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.018
Emerging targets of inflammation and tear secretion in dry eye disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.02.006
Mini-gut: a promising model for drug development.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.06.006
Recent developments in liposomal drug delivery systems for the treatment of retinal diseases.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.004
Targeting P2X7 receptors as a means for treating retinal disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.029
Multiscale modelling of drug mechanism and safety.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.12.009
Accelerated drug discovery by rapid candidate drug identification.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.03.026
Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.07.005
The Horizon Scanning System at The Italian Medicines Agency.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.010
Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.10.002
Physiologically based ocular pharmacokinetic modeling using computational methods.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.039
Collaborative drug discovery and the Tres Cantos Antimalarial Set (TCAMS).
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.04.005
Impact of dosing schedule in animal experiments on compound progression decisions.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2018.11.006
Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.10.001
Novel insights into the role of urotensin II in cardiovascular disease.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.08.005
Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.12.008
CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.07.002
Adverse drug reactions on sexual functioning: a systematic overview.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.01.012
Correlates of time to approval and other clinical development periods.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.027
Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.02.007
Drug discovery: a research sector stricken in France that can sometimes pay off.
来源期刊：Drug discovery todayDOI：10.1016/j.drudis.2019.05.002

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACADEMIC EMERGENCY MEDICINE封面

ACADEMIC EMERGENCY MEDICINE

学科领域：医学
影响因子：3.2
中科院分区： 2区
ACADEMIC RADIOLOGY封面

ACADEMIC RADIOLOGY

学科领域：医学
影响因子：3.9
中科院分区： 2区
APPETITE封面

APPETITE

学科领域：医学
影响因子：3.8
中科院分区： 2区
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA封面

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA

学科领域：医学
影响因子：3.1
中科院分区： 2区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学2区
PHARMACOLOGY & PHARMACY 药学
2区
是
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学2区
PHARMACOLOGY & PHARMACY 药学
2区
否
是
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学2区
PHARMACOLOGY & PHARMACY 药学
2区
否
是